Sam Caster Presentation Transcription


Well, I think one of the things that is exciting me these days is our own group saying that Acemannan is becoming well known out there.

You know, over the years when you say Acemannan, people go, what?

And now people are going, yeah.

I saw something about that on the Internet.

So I think that it’s exciting to hear that.

Of course, we…

I think we had more health care professionals at this event per capita than any we’ve had before.

And so we’re attracting really good quality people.

We’re attracting people that really care about the health care system and the alternative that we provide people, and we’re attracting folks that just want to be part of a movement that’s loaded with something like Acemannan and buy one, give one, and all the things that we do.

So, yeah, my takeaway is I just get the sense that people feel like we’re on the verge of momentum.

I told the group that about every two years, Lancet, which is one of the leading medical journals in the world, puts out an article that’s entitled the global burden of disease.

And, essentially, what they do is they just kind of bring everybody up to speed on where we’re at.

And you would think with all the money that’s in sick care that we would be getting our arms around some of our worst conditions and actually doing better.

But every report, basically, is the thing that’s getting worse.

It’s getting more expensive.

The cost of managing poor health and disease has grown at twice the rate of inflation, which means it’s completely unsustainable.

So something needs to be done.

You know, it’s interesting during that presentation on Friday night you were just referring to when Danny was interviewing me, it’s kind of like…

Her first question is what…

When you sat down with Carrington Labs and first saw Acemannan, what excited you the most?

And I said, you gotta go back to the 1980s and understand that there was a pandemic similar to, COVID, only a lot worse because it was a 100% lethal.

There was no treatment for it, and it was called AIDS.

And I said, what happened at Carrington Labs is some of the patients started reporting, AIDS patients, that their quality of life was dramatically improving.

Some of the tumors were subsiding, and their immune systems were starting to function again.

And so Carrington did a 15 patient study.

In those days, you could actually do a study in the state that you’re in.

It wasn’t federal.

It was state level.

So they did a study on 15 patients with AIDS and saw a 74% improvement in all the biomarkers.

There was a lady from the NIH, she’s a virologist, that was tasked with looking at all current drugs to see if anything could kill the AIDS virus because there was nothing.

There was no treatment.

And looking at all the oncology drugs, whether they were ever approved or not, she found a drug called AZT that killed the AIDS virus.

But it was developed originally for leukemia, it was so toxic it never got to the market because the drug killed more people than leukemia did.

But since it killed AIDS in the test tube, that was a revelation.

Now this virologist by the name of Jazmir Kalon said, I don’t recommend AZT because I don’t think these patients can survive it without transfusions every time they take it.

She saw Carrington’s report on these 15 patients, and she went, this is…

This can’t be right.

So she took Acemannan into her lab, and she tested in cell line cultures with AIDS and found that in a dose response study, and I showed the paper, that night, Friday night that was published, she saw that she could stop the replication of the AIDS virus 100%.

She was, like, ecstatic.

So she went to her boss and said, hold up on AZT.

I’ve got something that’s dynamic.

It’s nontoxic.

It’s showing more benefits than anything.

It’s called Acemannan.

It’s a plant-based molecule, hasn’t even been approved as a drug yet, and her boss just basically said there’s no way that we’re allowing something like that into the marketplace.

It’s going to be a major pharmaceutical company that we support.

Her boss was Anthony Fauci.

And every time I say that, people go, what?

Well, of course.

And so we gave away a book, and I gave away this book, the real Anthony Fauci.

The chapter on the pandemic template, AIDS and AZT, it is just classic.

Anyway, so I said, you know, it was the fact that here was the most difficult health situation in the world being remedied by optimizing these patients’ immune systems with Acemannan, and I just couldn’t believe it.

We also talked about some of the early cancer studies they did at Texas A & M by infusing a mouse model called Norman sarcoma tumors.

It’s a cancer that’s a hundred percent lethal.

So if you want to test a drug, you always test it against that because nothing survives.

They’ve got ninety percent survival rate.

And so you can imagine the research team at Carrington was just on cloud nine.

Their sock went through the roof.

Between the AIDS and the cancer, it was like, this is going to be the miracle drug of all miracle drugs.

But those in power, those that have the ability to approve or disapprove or reject, I should say, any new drug application rejected Carrington.

And, of course, we all have heard the story they rejected because by law, you have to prove a lethal dose level that can kill fifty percent of the mice you injected into, which they can then extrapolate for use in humans, and Acemannan couldn’t kill anything.

Didn’t matter what the dosage was, couldn’t kill a thing, and so it was rejected.

So when I heard that story, I thought, who wouldn’t want to bring this technology into the marketplace?

But I told the people, I said, you know, what’s interesting is, gosh, it’s thirty years later, people still go, I’ve never heard of Acemannan.

It’s the best kept secret in health care.

Of course, there was no Internet in those days.

There was no way of sharing technology and seeing people respond by the tens of thousands all over the world.

That’s what’s really changed in our industry is social media.

And talking with Danny Morgan, you know, just about the notoriety that Acemannan is now getting online, you can’t help but just absolutely understand that we’re on the tipping point of massive growth.

And I also mentioned that, you know, at the first symposium on social entrepreneurship that I went to, the group identified what is the biggest problem in the world that lends itself best to a social entrepreneur solution, and it was Acemannan and its ability to shift sick care to, health care.

But everybody there knew the obstacle.

This change is not going to be promoted from within.

We already had seen that it was rejected and basically buried in a mountain of bureaucracy.

And so it would take a people movement in order to get people both the education, the science, which there’s plenty of, as well as people’s responses that struggle with every kind of health condition known to mankind.

What we now know is that optimizing a person’s immune system is absolutely the number one strategy for any kind of condition, because the human body yields itself if it can get the proper support, and that’s what Acemannan does better than anything else out there.

I also mentioned that, you know, our…

Even in spite of Acemannan still being sort of not really well known out there, I mean, people are discovering it every day, our growth has been growing at a compounded rate of about 25% a year.

Now any company in America would just be thrilled with that level of growth.

But in our industry, you can hit a dynamic that is called momentum that starts doubling your volume.

And I think everybody feels we’re sort of right on the edge of getting to that place.

The growth that we’ve experienced has allowed us to start really investing in our company.

After the first year, we will have finished a complete redo of our IT platform and back office, which will include AI managers that allow you to just vocally ask questions on your app about anything you want to know in your business and get an answer instead of trying to research it.

We have AI managers now for our customer service, groups so they can find tracking of orders and commissions and anything they’re asked sort of in lightning speed.

That will ultimately allow us to develop a new app.

Most of you know that we’ve had to license the apps that we’ve had, and they’re serviceable.

I mean, they provide us the…

But, you know, we’ve had to do a lot of the programming on these apps ourselves to facilitate our particular use of them.

We’ll develop and roll out our own app so that it’s us, and we don’t have to beg another company to please keep up with the types of reports and things that we want.

We’ll update our website.

I mean, everything after the first of the year, that’s basically when all of this gets finished because we’ve been working on it for about six months.

We’ve also opened a new warehouse.

We’re right now doing our international shipping from that warehouse.

It’s a warehouse that we own and operate.

You know, I mean, there’s the debate on whether that’s a good investment or not because you can get three outside vendors to do your shipping.

But, you know, our marketing team came to us and said, we’d like to start including a lot of information in our packaging.

We want to communicate with our customers a lot more effectively, and one of the best places to do that is through their product orders.

And when you’re licensing outside vendors, I mean, they nickel and dime you to death on every little thing that you want to add to a box.

And pretty soon, the cost of shipping is more than the cost of the product.

So this gives us the ability to do anything that we want to do with our shipping, and I think we’ll also be able to provide better service, better tracking because it belongs to us.

So look for a lot of that sort of thing to happen after the first of the year.

Listen.

Our goal is to put Alovéa in a position to facilitate rapid growth, And I think that that’s what we’re doing, and I’m excited about the opportunity that everybody on this call has for bringing the number one solution to the world’s biggest problem into the marketplace.

Of course, because we’re a buy one get one for those who want their life’s work to account for more than just a paycheck, you’ve ended up in the right place.